NCT01223898View on ClinicalTrials.gov

To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Chronic Myeloid Leukemia
Interventions
DRUG

Tasigna

Trial Locations (5)

60590

Novartis Investigative Site, Frankfurt/M

68167

Novartis Investigative Site, Mannheim

89081

Novartis Investigative Site, Ulm

07740

Novartis Investigative Site, Jena

G12 0YN

Novartis Investigative Site, Glasgow

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY